The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > COMMENTARY
COMMENTARY
- COMMENTARY 6 articles
July 25, 2005
- Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (3)
July 4, 2005
- Former Reviewers' Interviews Make OPIR Report Exciting
June 27, 2005
- Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (2)
June 27, 2005
- Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (1)
June 20, 2005
- Special Contribution
May 16, 2005
- Japan's Most Admired Pharma Companies P. Reed Maurer President, NPP
April 18, 2005
- PRTM Shows Results of Investigational Drug Survey
March 14, 2005
- <Special Comtribution>
March 7, 2005
- <Special Comtribution>
March 7, 2005
- JPMA Update (12)
November 22, 2004
- JPMA Pudate(11)
November 15, 2004
- JPMA Update (10)
November 8, 2004
- JPMA Update (9)
November 1, 2004
- JPMA Update (8)
October 25, 2004
- JPMA Update (7)
October 18, 2004
- JPMA Update (6)
October 11, 2004
- <Special Contribution>
October 4, 2004
- JPMA Update (5)
October 4, 2004
- JPMA Update(4)
September 27, 2004
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…